Background: Although it is well known that aspirin causes gastroduodenal mucosal injury and that aspirin-induced gastroduodenal mucosal injury is often asymptomatic, the prevalence and independent factors for gastroduodenal mucosal injury have not been clarified in asymptomatic patients taking low-dose aspirin and gastroprotective agents. Aim: To clarify the prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents. Design: Prospective observational study. Methods: We performed endoscopy in 150 asymptomatic patients taking low-dose aspirin and gastroprotective agents for at least 3 months. Results: Gastroduodenal ulcers/erosions were observed in 37.3% [ulcers (4.0%); erosions (34.0%)]. Univariate logistic regression analyses showed that proton-pump inhibitor (PPI) use was negatively associated with gastroduodenal
Introduction
Low-dose aspirin (75-325 mg/day) is widely used for primary and secondary prevention of cardiovascular events and prevention of coronary stent thrombosis. [1] [2] [3] [4] [5] The use of low-dose aspirin is associated with a 2-to 4-fold increased risk of upper gastrointestinal complications such as gastroduodenal ulcers and gastrointestinal bleeding. 6, 7 There are only a few endoscopic studies investigating the exact prevalence of gastroduodenal mucosal injury in patients taking low-dose aspirin [8] [9] [10] (Table 1) . Yeomans et al. 8 performed endoscopy in 187 patients taking low-dose aspirin and no gastroprotective agents and found gastroduodenal ulcers in 10.7% and gastroduodenal erosions in 63.1%.
Nema et al. 9 performed endoscopy in 190 patients taking low-dose aspirin and found gastroduodenal ulcers/erosions in 48.4%. These studies included patients with and without upper gastrointestinal symptoms. Because it is well known that aspirin-induced gastroduodenal mucosal injury is often asymptomatic, 8, 11 it would be expected that some of asymptomatic patients taking low-dose aspirin may have gastroduodenal erosions/ulcers. Niv et al. 10 investigated the prevalence of gastroduodenal ulcers/erosions in 46 asymptomatic patients taking low-dose aspirin and found gastroduodenal erosions/ulcers in 47.8%. In their study, only 24% of patients were taking a gastroprotective agent. Therefore, the prevalence and independent factors for gastroduodenal ulcers/erosions have not been clarified in asymptomatic patients taking low-dose aspirin and gastroprotective agents. In the present study, we examined these points.
Methods
The present study was conducted between January 2008 and December 2008 at three centers (Oita University Hospital, Oita Nakamura Hospital and Koseiren Tsurumi Hospital), in accordance with the Declaration of Helsinki and its amendments. The study protocol was approved by the ethics committee at Oita University Hospital, and written informed consents were obtained from all patients before enrollment.
Patients
Eligible patients who were hospitalized to cardiology department of the three hospitals or attending cardiology outpatient clinics of these hospitals and who were taking low-dose aspirin and gastroprotective agents for the preceding !3 months were registered in this study. Inclusion criteria were as follows: age >20 years; no upper gastrointestinal symptoms (epigastric pain, burning or discomfort, heartburn, pain, acid regurgitation, nausea and bloating); no changes of gastroprotective agents within the preceding 3 months; no history of operations for the esophagus, stomach and duodenum; neither acute coronary syndrome nor stroke within the preceding 3 months; severe chronic heart failure (New York Heart Association functional Class IV); and no malignant diseases. Finally, 150 patients (102 men and 48 women, mean age of 71.6 AE 10.0 years) were enrolled in this study and underwent esophagogastroduodenal endoscopy.
Demographic data
The following demographic data were collected: age, gender, body mass index, coronary risk factors, alcohol consumption, histories of cardiovascular disease, peptic ulcers and eradication of Helicobacter pylori, and current medications. Patients who reported that they drank alcohol everyday were considered as regular alcohol drinkers. Standard-dose proton-pump inhibitors (PPIs) were defined as lansoprazole of 30 mg/day, omeprazole of 20 mg/day and raveprazole of 20 mg/day, and low-dose PPIs were defined as lansoprazole of 15 mg/day, omeprazole of 10 mg/day and raveprazole of 10 mg/day.
Helicobacter pylori infection status
Helicobacter pylori infection was examined using a urine-based enzyme-linked immunosorbent assay (Otsuka Pharmaceutical, Tokyo, Japan). The sensitivity, specificity and accuracy of this assay has been shown to be almost equivalent to serum-based enzyme-linked immunosorbent assays for identifying patients with H. pylori infection.
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Endoscopic examinations
Esophagogastroduodenal endoscopy was performed without cessation of aspirin because cessation of aspirin may affect gastroduodenal mucosal status. An ulcer was defines as a mucosal defect having significant depth, measuring at least 3 mm over its longest diameter. An erosion was defined as a mucosal defect <3 mm. The evaluation was performed by experienced endoscopists who were blinded to all clinical data.
Statistical analysis
Continuous data are expressed as mean AE SD or median (first-third quartiles), and categorical data are expressed as n (%). Univariate and multivariate logistic regression analyses were performed to determine factors for gastroduodenal ulcers/erosions. A multivariate logistic regression analysis was performed using explanatory variables that showed P < 0.3 in univariate logistic regression analyses. A P-value < 0.05 was considered to be statistically significant. All analyses were performed using SS 12.0J for Windows (SPSS Inc, Tokyo, Japan).
Results
Patient characteristics are shown in Table 2 . The doses of aspirin were 81 mg/day in five patients (3.3%), 100 mg/day in 143 patients (95.3%) and 200 mg/day in two patients (1.3%). The enteric coated and buffered formulations were being taken in 145 patients (96.7%) and five patients (3.3%), respectively. PPIs [lansoprazole (n = 31), omeprazole (n = 15) and raveprazole (n = 7)], H 2 blockers [famotidine (n = 37), ranitidine (n = 14) and nizatidine (n = 4)] and mucoprotective agents [rebamipide (n = 15), cetraxate (n = 14), teprenone (n = 12), azulenesulfonate (n = 6), plaunotol (n = 2), isoglandin (n = 2), ecebet (n = 1) and sofalcone (n = 1)] were being taken in 53 patients (35.3%), 55 patients (36.7%) and 53 patients (35.3%), respectively. Gastroduodenal ulcers/erosions were observed in 56 patients (37.3%): ulcers in six (4.0%); erosions in 51 (34.0%) (Figure 1) . One patient had a gastric ulcer and gastric erosions. Table 3 shows detailed data of six patients with a gastric or duodenal ulcer. Three of six patients with a gastric or duodenal ulcer had a positive H. pylori urinary test. Table 4 shows results of univariate and multivariate logistic regression analyses to determine factors for gastroduodenal ulcers/erosions. Univariate logistic regression analyses showed that PPI use was showed that PPI use was the only independent factor for gastroduodenal ulcers/erosions (OR 0.35, 95% CI 0.14-0.86, P = 0.02). None of 53 patients with PPI use had any gastroduodenal ulcers. Figure 2 shows the prevalence of gastroduodenal erosions in 11 patients with standard-dose PPI use (lansoprazole of 30 mg/day in seven patients, omeprazole of 20 mg/day in three patients and raveprazole of 20 mg/day in one patient) and 42 patients with low-dose PPI use (lansoprazole of 15 mg/day in 24 patients, omeprazole of 10 mg/day in 12 patients and raveprazole of 10 mg/day in six patients). The former tended to have a lower prevalence of gastroduodenal erosions than the latter (0% vs. 28.6%, P = 0.052).
Discussion
The major findings of the present study are as follows: (i) gastroduodenal ulcers/erosions were observed in 37.3% [ulcers (4.0%); erosions (34.0%)] of 150 asymptomatic patients taking low-dose aspirin and gastroprotective agents; (ii) PPI use was the only independent factor for gastroduodenal ulcers/erosions; (iii) none of patients with PPI use had any gastroduodenal ulcers; and (iv) patients with standard-dose PPI use tended to Other abbreviations are as Tables 1 and 2. OR: odds ratio, CI: confidence interval. have a lower prevalence of gastroduodenal erosions than those with low-dose PPI use. Low-dose aspirin causes gastrointestinal mucosal injury through topical injury to the mucosa and systemic effects by prostaglandin depletion. 14, 15 Aspirin is non-ionized by the acid environment of the stomach and accumulates in gastric mucosal cells. Then, it alters the permeability of the cell membrane due to iron trapping and back-diffuses H + irons from the gastrointestinal lumen, leading to cellular toxicity. Inhibition of cyclo-oxygenase-1 pathway decreases production of prostaglandins that have protective effects on the stomach through the following mechanisms: an increase in mucosal blood flow, stimulation of the synthesis and secretion of mucus and bicarbonate, and promotion of epithelial proliferation. Depletion of prostaglandins makes a gastric environment more susceptible to topical attacks by endogenous factors including acid, pepsin and bile salts. In addition, low-dose aspirin promotes gastrointestinal bleeding through its antiplatelet effect.
It is well known that aspirin-induced gastroduodenal mucosal injury is often asymptomatic 8, 11 because of an aspirin induced increase in a sensory threshold. 11 Niv et al. 10 investigated the prevalence of gastroduodenal ulcers/erosions in 46 asymptomatic patients taking low-dose aspirin and found these lesions in 47.8%. In their study, only 24% of patients were taking a gastroprotective agent. Therefore, the prevalence and independent factor for gastroduodenal ulcers/erosions have not been clarified in asymptomatic patients taking low-dose aspirin and gastroprotective agents. In addition, no information is available on the prevalence of gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and a PPI, which has been shown to be effective in the prevention of aspirin-induced gastroduodenal ulcers. 18 Therefore, it would be clinically important to examine these points. In the present study, gastroduodenal ulcers/erosions were observed in 37.3% of 150 asymptomatic patients taking low-dose aspirin and gastroprotective agents. The prevalence of gastroduodenal ulcers/ erosions was relatively lower in the present study compared to the prevalences in previous studies. [8] [9] [10] This is thought to be because the present study consisted of asymptomatic patients taking gastroprotective agents together with low-dose aspirin. In the present study, none of 53 patients with PPI use had any gastroduodenal ulcers, and PPI use was the only negative independent factor for gastroduodenal ulcers/erosions, suggesting an efficacy of PPIs in the prevention of aspirin-induced gastroduodenal ulcers/erosions. It has been already shown that PPI therapy prevents upper gastrointestinal bleeding 16, 17 and gastroduodenal ulcers 18 in patients taking low-dose aspirin. Because gastric acid more easily injures gastroduodenal mucosae under the environment of prostaglandin depletion, it would be expected that PPI therapy can protect aspirin-induced gastroduodenal mucosal injury through its strongly suppressive effect on gastric acid. Of interest, in the present study, patients with standard-dose PPI use had no gastroduodenal erosions and tended to have a lower prevalence of gastroduodenal erosions than those with low-dose PPI use. These suggest that standard-dose PPI therapy may be more effective in the prevention of aspirin-induced gastroduodenal mucosal injury than low-dose PPI therapy. No information is so far available with regard to the association between the dose of PPIs and the preventive effects on aspirin-induced gastroduodenal mucosal injury. Future studies are required to clarify whether standard-dose PPI therapy is more effective in the prevention of aspirin-induced gastroduodenal mucosal injury than low-dose PPI therapy.
In the present study, H 2 blocker use was not a negative independent factor for gastroduodenal ulcers/erosions. This might be because the majority (89%) of patients with H 2 blocker use was taking a low-dose H 2 blocker (famotidine of 20 mg/day, ranitidine of 150 mg/day or nizatidine of 150 mg/day). It was recently demonstrated that standard-dose famotidine (40 mg/day) is effective in the prevention of gastroduodenal ulcers in patients taking low-dose aspirin. 20 The association between the dose of H 2 blockers and aspirin-induced gastroduodenal mucosal injury remains to be further investigated.
The present study has a few limitations. First, we did not evaluate the exact administration duration and compliance of gastroprotective agents, which would affect gastroduodenal mucosal status. Second, the prevalences of PPI use and H 2 blocker use were relatively higher in the present study compared to those in previous studies. 8, 9, 10 A kind of gastroprotective agents being used would naturally affect the prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin. We did not investigate the reason why the gastroprotective agent was selected in each patient, but the relatively higher prevalences of PPI use and H 2 blocker use might be partly because 30% of patients had a history of a peptic ulcer. In addition, the increasing use of PPIs in patients taking low-dose aspirin in Japan is likely to have contributed to the relatively higher prevalence of PPI use in the present study. Thirds, because the present study included only asymptomatic patients, the associations between gastroprotective agents and gastroduodenal ulcers/erosions indicated by the present study may not be generalized in the whole of patients taking low-dose aspirin.
In conclusion, gastroduodenal ulcers/erosions were observed in about one-third of asymptomatic patients taking low-dose aspirin and gastroprotective agents, and PPI use was a negative independent factor for gastroduodenal ulcers/erosions in those patients. In addition, standard-dose PPI therapy might be more effective in the prevention of aspirin-induced gastroduodenal mucosal injury than low-dose PPI therapy.
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